Orchid Pharma Files FY26 Business Responsibility and Sustainability Report

Orchid Pharma Ltd has submitted its Business Responsibility and Sustainability Report (BRSR) for the Financial Year 2025-26, as mandated by SEBI regulations. The report, which is part of the company's Annual Report, details its operations, employee data, and market reach. Key disclosures include the company's primary business activity of manufacturing and sales of Active Pharmaceutical Ingredients (APIs) and products, accounting for 97% of its turnover. The report also outlines the company's operational footprint with 6 plants and 3 offices nationally, serving 15 states and 52 countries internationally, with exports contributing 64.55% to total turnover. Employee statistics and sustainability initiatives are also covered.